Catalytic ozonation process using a MgO nano-catalyst to degrade methotrexate from aqueous solutions and cytotoxicity studies in human lung epithelial cells (A549) after treatment

使用 MgO 纳米催化剂的催化臭氧化工艺降解水溶液中的甲氨蝶呤,并进行处理后对人肺上皮细胞 (A549) 的细胞毒性研究

阅读:14
作者:Abdolazim Alinejad, Hamed Akbari, Mansour Ghaderpoori, Ali Khani Jeihooni, Amir Adibzadeh

Abstract

Pharmaceutical compounds which enter the environment are classified as emerging pollutants. Among different drug compounds, anti-cancer drugs like methotrexate are of more concern due to their mutagenic, carcinogenic, and genotoxic properties. Therefore, the main objective of this study was to use catalytic ozonation processes (COPs) as novel advanced oxidation processes to degrade methotrexate from aqueous solutions. The calcination method was used to obtain a nitrate magnesium oxide nano-catalyst. The main variables considering the effect of single ozonation processes (SOPs) and COPs on the target pollutant were initial methotrexate concentration, contact time, solution pH, and MgO dosage. The BET results indicated that the surface area of the MgO nano-catalyst was 140.031 m2 g-1. Based on the BJH plot, the size of the MgO nano-catalyst and average pore volume were 44.5 nm and 0.4454 cm3 g-1, respectively. The weight percent of Mg and O was 61.09% and 38.91%, respectively. In acidic and alkaline pH, the degradation rate of methotrexate showed a higher increase in SOPs and COPs than at neutral pH. The degradation rate of methotrexate decreased with increasing concentration. By increasing the contact time, the degradation rate of methotrexate of both SOPs and COPs increased. Actually, the methotrexate degradation in COPs was faster than in SOPs. When using tert-butanol as a scavenger, the reduced removal efficiency in SOPs and COPs was 32% and 31%, respectively.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。